research use only

Etoricoxib COX inhibitor

Cat.No.S4651

Etoricoxib (Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia) is a new COX-2 selective inhibitor with anti-inflammatory, antipyretic, analgesic, and potential antineoplastic properties.
Jump to

Quality Control

Batch: S465101 DMSO]71 mg/mL]false]Ethanol]46 mg/mL]false]Water]Insoluble]false Purity: 99.61%
99.61

Solubility

In vitro
Batch:

DMSO : 71 mg/mL (197.85 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 46 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 358.84 Formula

C18H15ClN2O2S

Storage (From the date of receipt)
CAS No. 202409-33-4 Download SDF Storage of Stock Solutions

Synonyms Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia SMILES CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
COX-2
In vivo
The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-08)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07370532 RECRUITING
Parkinson Disease
Ihab Elsayed Hassan
2026-01-30 PHASE2
NCT05683574 WITHDRAWN
Third Molar Extraction
Eurofarma Laboratorios S.A.
2026-05-30 PHASE3
NCT07661030 NOT_YET_RECRUITING
Gout
First Affiliated Hospital of Wenzhou Medical University
2026-07-30 PHASE4
NCT06863701 RECRUITING
Gout Arthritis; Gout Attack
Laboratorios Silanes S.A. de C.V.
2025-01-27 PHASE3
NCT06863662 COMPLETED
Acute Low-back Pain; Muscle Spasm; Back Pain
Laboratorios Silanes S.A. de C.V.
2024-09-18 PHASE3
NCT07328022 COMPLETED
Bursitis; Tendinitis; Synovitis
Laboratorios Silanes S.A. de C.V.
2025-05-14 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map